(secondQuint)Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis.

 This study consisted of a Phase I non-randomized dose escalation phase to determine the maximum tolerated dose and a randomized Phase II component to assess preliminary efficacy.

 Nanoparticle paclitaxel was administered by intracoronary catheter following either successful and uncomplicated stenting of de novo lesions in native coronary arteries or following successful and uncomplicated balloon angioplasty of instent restenosis (ISR) lesions.

.

 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis@highlight

The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following angioplasty for in-stent restenosis.

